Topic Primary open-angle glaucoma (POAG) is a highly prevalent condition worldwide and
the most common cause of irreversible sight loss. The objective is to assess the comparative …

Prostaglandins are approved by the European Glaucoma Society guidelines as first-line
treatment for glaucoma. This review focuses on latanoprost, an ester prodrug of …

Glaucoma is the main cause of irreversible visual loss worldwide, and comprises a group of
progressive, age-related, and chronic optic neuropathies. Prostaglandin analogs are …

Background: To evaluated and compared the efficacy and safety of 3 prostaglandin
analogues (0.005% latanoprost, 0.004% travoprost, and 0.03% bimatoprost) in treatment of …

Over the last 12 years, the pharmacological management of glaucoma and ocular
hypertension has significantly changed with the introduction of the prostaglandin analogs …

Elevated intraocular pressure (IOP) is a major, and currently the only, modifiable risk factor
that has been shown to reduce the risk of glaucoma onset and progression. Diurnal …

Current management of glaucoma entails the medical, laser, or surgical reduction of
intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate …

Prostaglandin analogs (PGA) are powerful topical ocular hypotensive agents available for
the treatment of elevated intraocular pressure (IOP). Latanoprost 0.005% and travoprost …

Purpose To evaluate the effects of a single bimatoprost implant administration on 24-hour
intraocular pressure (IOP) lowering at 8 weeks, and 1-year IOP-lowering efficacy and safety …

Background: Network meta-analysis compares multiple treatment options for the same
condition and may be useful for developing clinical practice guidelines. Purpose: To …